Gateway to Think Tanks
来源类型 | Perspectives |
规范类型 | 论文 |
DOI | https://doi.org/10.7249/PE264 |
来源ID | PE-264-SANI |
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential | |
Andrew W. Mulcahy; Jakub P. Hlavka; Spencer R. Case | |
发表日期 | 2017 |
出版年 | 2017 |
页码 | 20 |
语种 | 英语 |
结论 | The Cost Savings Potential of Biosimilars
The Future of the Biosimilars Market
The Beneficiaries of Cost Savings
|
摘要 | The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the 2010 Patient Protection and Affordable Care Act (ACA), authorized the U.S. Food and Drug Administration (FDA) to create a new regulatory approval pathway for biosimilars, which are biologic drugs that are very similar to already approved "reference" biologics in terms of potency, safety, and efficacy, but are manufactured by different companies. In the seven years since the ACA, many drug manufacturers worked to push new biosimilars through development and FDA review. As of July 2017, there were three marketed biosimilars and two more that were approved by the FDA but not yet marketed. BPCIA's shorter, lower-cost biosimilar approval pathway was designed to introduce competition among biologic manufacturers. This Perspective estimates potential future savings from biosimilars in the United States, summarizes the experience to date with the first marketed biosimilar in the United States, and discusses key policy issues surrounding biosimilars. We estimate that biosimilars will reduce direct spending on biologic drugs by $54 billion from 2017 to 2026, or about 3 percent of total estimated biologic spending over the same period, with a range of $24 to $150 billion. While our estimate uses recent data and transparent assumptions, we caution that actual savings will hinge on industry and regulatory decisions as well as potential policy changes to strengthen the biosimilar market. |
主题 | Health Care Costs ; Health Economics ; Health Insurance ; Pharmaceutical Drugs |
URL | https://www.rand.org/pubs/perspectives/PE264.html |
来源智库 | RAND Corporation (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/112570 |
推荐引用方式 GB/T 7714 | Andrew W. Mulcahy,Jakub P. Hlavka,Spencer R. Case. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. 2017. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
x1545057977126.jpg(8KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
RAND_PE264.pdf(243KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。